Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02139163Recruiting

Epidemiological Study on Community Acquired Pneumonia

Role: lead

NCT02574143Unknown

The PROspective German NOn-CF bronchiectaSIS Patient Registry

Role: collaborator

NCT01892488Phase 4Completed

Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD

Role: collaborator

NCT00887276Phase 4Terminated

Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia

Role: collaborator

All 4 trials loaded